Top 10 Best Penny Stocks to Buy Now Under $1: Trading in penny stocks carries substantial risks and the allure of above-average returns, making it a venture that demands careful consideration and caution. Due to the inherent uncertainties, only a limited number of full-service brokerages provide access to penny stocks for their clients.
In this article, we will take a look at the 10 best penny stocks to buy under $1 that will explode like GEE Group Inc. (JOB), Cybin (CYBN), Tingo Group (TIO), Jaguar Health (JAGX), Netcapital (NCPL), ClearOne (CLRO) S&W Seed Co. (SANW)
As we enter the third quarter earnings season, optimism among investors is on the rise, with growing hopes on Wall Street for a positive conclusion to 2023, defying earlier recession concerns. NB Private Wealth’s Shannon Saccocia, speaking to CNBC, envisions a potential year-end market surge fueled by a robust economy, strong earnings, and resilient consumer spending.
However, Saccocia cautions that if the market reaches July highs, valuation concerns may resurface. Neil Hennessy, Chief Market Strategist at Hennessy Funds, shares a bullish outlook, citing companies in excellent shape with strong cash flows and fundamentals.
He attributes his optimism to wage growth and low unemployment, noting a shift in consumer behavior towards reluctance to sacrifice spending despite potential inflation, especially among the younger population accustomed to easy access to money.
10 Best Penny Stocks to Buy Less Than $1
- GEE Group Inc. (JOB)
- Cybin (CYBN)
- Invitae Corporation (NYSE:NVTA)
- Tingo Group (TIO)
- Jaguar Health (JAGX)
- Chimerix, Inc. (NASDAQ:CMRX)
- Netcapital (NCPL)
- ClearOne (CLRO)
- Kezar Life Sciences, Inc. (NASDAQ:KZR)
- S&W Seed Co. (SANW)
GEE Group Inc. (JOB) Company Overview
GEE Group Inc. (Nasdaq: JOB) stands as a national staffing and recruiting entity, catering to diverse sectors such as information technology, legal, engineering, finance, accounting, and healthcare. The company’s portfolio includes well-known brands like Ashley Ellis, General Employment, and Omni One.
the latest GEE Group Inc. (JOB) stock quote, historical data, and crucial news to support your stock trading and investment decisions. Stay informed with real-time stock prices and comprehensive financial insights on GEE Group Inc. through Moneymystica including an opening price of 0.55, a market cap of 62.46M, a P/E ratio of 7.54, and a 52-week range from a high of 0.80 to a low of 0.36.
GEE Group Inc. (JOB) Financial Details
| Quarterly Financials (USD) | Jun 2023 | Y/Y |
|---|---|---|
| Revenue | $38.17M | +7.16% |
| Net income | $7.88M | +199.13% |
| Diluted EPS | $0.07 | +250% |
| Net profit margin | 20.63% | +222.34% |
| Earnings Calls | Previous | EPS | Revenue |
|---|---|---|---|
| Jun 2023 | Beat 602.00% | – | Miss -1.96% |
Cybin (CYBN) Stock Company Overvview
Cybin (NYSE: CYBN) specializes in the development of proprietary psychedelic-based therapeutics targeting disorders such as major depressive disorder, alcohol use disorder, anxiety disorders, and beyond. Headquartered in Canada, the company is at the forefront of innovative solutions in the field.
Explore Cybin (CYBN) stock price with opening price of 0.4620 USD key metrics, including a 52-week range from a high of 0.74 to a low of 0.21.
CYBN Stock Financial Update
| Quarterly Financials (CYBN) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | – | – |
| Net income | -$11.89M | +19.22% |
| Diluted EPS | -$0.05 | +16.67% |
| Net profit margin | – | – |
Invitae Corporation (NYSE:NVTA)
Invitae Corp (It is one the 10 Best Penny Stocks to Buy) has experienced a significant 73% decrease in its shares over the past year. However, there was a recent surge in Invitae Corporation (NYSE: NVTA) shares following FDA approval for the Invitae Common Hereditary Cancers Panel—a test designed to identify cancer-related genes.
According to Insider Monkey’s database, 17 hedge funds, including the notable ARK Investment Management led by Catherine D. Wood, held stakes in Invitae Corporation (NYSE: NVTA). ARK Investment Management stands as the largest stakeholder with a substantial $36 million investment in the company.
Explore real-time market movements for Invitae Corp with the latest updates: Currently at 0.5403 USD, showing a decrease of 0.0028 USD (-0.52%) as of the last update on Nov 25 at 03:16 UTC+5.5. In the pre-market, it rose to 0.5499 USD, indicating an increase of 0.0096 USD (+1.78%) as of the last update at 19:05 UTC+5.5 with a market capitalization of 154.79M, a 52-week range from a high of 3.10 to a low of 0.36.
Invitae Corporation (NYSE:NVTA) Financial Overview
| Quarterly Financials (USD) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | $121.24M | +9.21% |
| Net income | -$942.11M | +212.83% |
| Diluted EPS | – | – |
| Net profit margin | -777.05% | +244.56% |
| Earnings Calls | Previous | EPS | Revenue |
|---|---|---|---|
| Sep 2023 | Beat 69.57% | Beat 0.20% | – |
Tingo Group, Inc. Common Stock (TIO) Company
Tingo Group (Nasdaq: TIO) is a diverse multinational financial and agricultural technology conglomerate with operations spanning Africa, Southeast Asia, and the Middle East. Headquartered in Montvale, New Jersey, the company offers a digital agricultural platform alongside services such as insurance, automotive services, payment processing, and merchant services. Tingo Foods, a subsidiary, transforms raw foods into essential staples and manages a commodity trading platform.
Tingo Group, Inc. Common Stock (TIO) opened at $0.6900, with a day range of $0.6650 to $0.7999, and a 52-week range spanning from $0.6315 to $5.6900. The market capitalization is $141.6M, with 205.22M shares outstanding and a public float of 173.93M.
Tingo Group (Nasdaq: TIO) Financial Overview
| Quarterly Financials (USD) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | $586.22M | +4161.26% |
| Net income | $20.74M | +370.43% |
| Diluted EPS | $0.04 | +166.67% |
| Net profit margin | 3.54% | +106.35% |
| Earnings Calls | Previous | EPS | Revenue |
|---|---|---|---|
| Sep 2023 | – – | – – | – – |
Jaguar Health, Inc. Common Stock (JAGX)
JAGX | Complete Jaguar Health Inc. stock (Nasdaq: JAGX) is dedicated to the development and commercialization of pioneering plant-based prescription medicines. Their existing products include an approved treatment for noninfectious diarrhea in specific adults with HIV/AIDS and an anti-diarrheal for chemotherapy-induced diarrhea in dogs, presently undergoing Phase 3 trials. Jaguar’s robust pipeline extends to additional diarrhea treatments, targeting prevalent conditions such as irritable bowel syndrome and irritable bowel disease.
With a 1-year target of $6.00, today’s high/low is not applicable, but the share volume is 183,215, and the average volume is 5,963,424. The previous close was at $0.3737, and the 52-week high/low stands at $11.4003/$0.21. Compliance status is not available, and the market cap is $18,525,790. The P/E ratio is not applicable, and the forward P/E for the next year is -0.06.
Jaguar Health, Inc. (Nasdaq: JAGX) Financial
| Quarterly Financials (USD) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | $2.81M | +10.7% |
| Net income | -$7.78M | +37.88% |
| Diluted EPS | -$0.38 | +95.7% |
| Net profit margin | -276.5% | +30.43% |
| Earnings Calls | Previous | EPS | Revenue |
|---|---|---|---|
| Sep 2023 | Beat 69.11% | Beat 14.35% | – – |
Also Read Related topics: top 5 small cap mutual funds 2022: Investment in top tax saving income | Nugget Rush (NUGX) is all set to Outperform Bitcoin and Solana in 2023 | General European Strategic invts inc symbol GESI Stock 2025.will the stock outperform?
Chimerix, Inc. Common Stock (CMRX) Overview
Chimerix, Inc. Common Stock (CMRX) Stock Quotes:
Chimerix, Inc. (NASDAQ: CMRX) is at the forefront of developing treatments for life-threatening diseases, earning it the 8th spot on the list of best penny stocks under $1, as endorsed by hedge funds. Out of the 910 hedge funds monitored by Insider Monkey, 19 had stakes in Chimerix, Inc. by the end of the Q2 of 2023. The leading investor during this period was Steven Boyd’s Armistice Capital, holding a substantial $3.8 million stake in the company.
Providing insights into its financial performance, Chimerix, Inc. reported second-quarter results in August. While GAAP EPS stood at -$0.21, surpassing estimates by $0.03, revenue experienced a 93.2% YoY decline, reaching $0.03 million and missing estimates by $0.24 million.
According to the latest market movements for Chimerix, Inc. (NASDAQ: CMRX): Currently at 0.9526 USD, reflecting a decrease of 0.0081 USD (-0.84%) as of the last update on Nov 25 at 02:32 UTC+5.5. In the pre-market, it rose to 0.9555 USD, indicating an increase of 0.0029 USD (+0.30%) as of the last update at 19:46 UTC+5.5.
Chimerix, Inc. (NASDAQ: CMRX) Financials
| Quarterly Financials (USD) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | $11K | +99.97% |
| Net income | -$23.99M | +109.94% |
| Diluted EPS | -$0.27 | +109.82% |
| Net profit margin | -218,054.55% | >9999.99% |
| Earnings Calls | Previous | EPS | Revenue |
|---|---|---|---|
| Sep 2023 | Miss -17.39% | Miss -89.72% | – – |
Netcapital Inc. Common Stock (NCPL) Overview
Netcapital (Nasdaq: NCPL), though the smallest company in this roundup, stands out as a notable player in the realm of equity crowdfunding. This fintech entity, headquartered in Boston, specializes in aiding private companies in raising capital online. Netcapital extends its support through onboarding, regulatory-document filing, and compliance review. Beyond its crowdfunding focus, the company also acts as an advisor to tech startups, providing valuable assistance in investment facilitation.
NCPL | Complete Netcapital Inc. stock Today’s High/Low, $0.33/$0.3047 ; Share Volume, 22,742 ; Average Volume, 178,877 ; Previous Close, $0.3299.
Netcapital (Nasdaq: NCPL) Financial
| Quarterly Financials (USD) | Jul 2023 | Y/Y |
|---|---|---|
| Revenue | $1.52M | +13.37% |
| Net income | -$491.66K | +862.53% |
| Diluted EPS | -$0.07 | +450% |
| Net profit margin | -32.35% | +772.56% |
ClearOne, Inc. (DE) Common Stock (CLRO)
ClearOne (Nasdaq: CLRO) stands as an audio-video company offering cloud-based conferencing and collaboration services tailored for professional home offices and commercial spaces. Headquartered in Salt Lake City, ClearOne serves a diverse clientele, counting Temple University, Rochester Institute of Technology, WebMD, and Marriott among its notable clients.
The latest ClearOne, Inc. (CLRO) stock quote today: Open $0.7895 ; Day Range 0.7800 – 0.8110 ; 52 Week Range 0.6350 – 2.6500 ; Market Cap $19.38M ; Shares Outstanding 23.96M
ClearOne, Inc. (CLRO) stock Financial
| Quarterly Financials (USD) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | $4.89M | +21.95% |
| Net Income | -$1.35M | +8.25% |
| Diluted EPS | -$0.06 | +20% |
| Net Profit Margin | -27.63% | +38.7% |
Kezar Life Sciences, Inc. Common Stock (KZR)
Kezar Life Sciences, Inc. (NASDAQ: KZR) is actively engaged in developing treatments for immune-mediated diseases and cancer. In a recent strategic move, the company announced plans to appoint a new CEO and undergo a workforce reduction of 41%, with the proceeds earmarked for supporting its PALIZADE mid-stage trial in lupus nephritis. Among the 910 hedge funds monitored by Insider Monkey, 21 held stakes in Kezar Life Sciences, Inc. (KZR), with Suvretta Capital Management, led by Aaron Cowen, leading the pack with a substantial $17.6 million stake in the company.
Explore Kezar Life Sciences, Inc. (KZR) stock performance with key metrics: opening at 0.92, reaching a high of 0.92, and a low of 0.88. The market capitalization stands at 65.49M, while the P/E ratio and dividend yield are currently unavailable. The 52-week range spans from a high of 7.89 to a low of 0.67. Stay informed for strategic investment decisions.
Kezar Life Sciences, Inc. (KZR) Financial
| Quarterly Financials (USD) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | $7M | – |
| Net Income | -$23.1M | +29.45% |
| Diluted EPS | – | – |
| Net Profit Margin | -330.04% | – |
S&W Seed Company Common Stock (NV) (SANW)
S&W Seed Co. (Nasdaq: SANW) is a leading producer of seeds for diverse crop products, encompassing alfalfa, sorghum, and stevia. The company employs both direct sales and dealer-distributors for seed distribution. At the forefront of innovation, S&W’s research and development initiatives involve hybrid crops, gene-edited alfalfa plants, and a sorghum solution designed to enhance yield.
SANW | Complete S&W Seed Co. (Nasdaq: SANW) stock performance, opening at 0.65 and reaching a high of 0.69, with a low of 0.65. The market capitalization stands at 29.54M, boasting a P/E ratio of 2.36. While the dividend yield is currently unavailable, the 52-week range extends from a high of 2.14 to a low of 0.60.
S&W Seed Co. (Nasdaq: SANW) stock Finacial overview
| Quarterly Financials (USD) | Sep 2023 | Y/Y |
|---|---|---|
| Revenue | $16.43M | +17.28% |
| Net Income | -$5.95M | +31.95% |
| Diluted EPS | -$0.14 | +27.27% |
| Net Profit Margin | -36.21% | +59.52% |
| Earnings Calls | Previous | EPS | Revenue |
|---|---|---|---|
| Sep 2023 | – – | Miss -8.71% | – – |
Conclusion: 10 Best Penny Stocks to Buy
Investing in companies within the technology and medical sectors, while promising significant returns, comes with inherent risks, given the high failure rate. Particularly, these are our picks for 10 Best Penny Stocks to Buy below $1 for an extended period face the threat of delisting from their respective exchanges. Without a natural price increase or strategic interventions like reverse stock splits, these stocks might find themselves relegated to the over-the-counter market, potentially leading to reduced liquidity. Investors in such ventures should remain vigilant and consider the associated uncertainties before making investment decisions.
DISCLAIMER: While the aforementioned (It is one the 10 Best Penny Stocks to Buy) stocks offer promising opportunities, it’s crucial to align your investment choices with your risk tolerance and objectives.
FAQ: 10 Best Penny Stocks to Buy
How can companies prevent delisting due to low stock prices?
Companies may take actions like reverse stock splitting to boost stock prices and prevent delisting.
What innovative projects is S&W Seed Co. (SANW) involved in?
S&W Seed Co. is engaged in innovative projects, including research and development of hybrid crops and gene-edited alfalfa plants.
What is the market capitalization of ClearOne (CLRO)?
ClearOne (CLRO) currently has a market capitalization of 29.54M USD.
What hedge funds are invested in Kezar Life Sciences, Inc. (NASDAQ:KZR)?
Kezar Life Sciences, Inc. (KZR) has garnered investments from 21 hedge funds, with Suvretta Capital Management holding a significant $17.6 million stake.
How does the stock performance of GEE Group Inc. (JOB) look?
GEE Group Inc. (JOB) currently has an open price of $0.65, reaching a high of $0.69, with a 52-week range from 0.60 to 2.14.
What is the potential long-term outlook for Chimerix, Inc. (NASDAQ:CMRX)?
Despite recent achievements, Chimerix’s alter its long-term bullish outlook, with analysts projecting share prices to reach $2.20 by the end of 2023, $2.50 in 2024, and $3.15 in 2025.
Which stocks are recommended for investment under $5?
For an attractive option under $5, Pitney Bowes Inc. (PBI) stands out. This well-established shipping and mailing company, with roots dating back to 1920, is currently trading at $3.92. Notably, it boasts an average one-year price target of $6 and an appealing dividend yield of 5.10%.
Which other are 10 Best Penny Stocks to Buy the best under $2?
Despite the inherent risks associated with stocks under $2, Pixelworks Inc. (PXLW) and Bolt Biotherapeutics Inc. (BOLT) present intriguing possibilities. Both valued under $2, these stocks have garnered “buy” or “strong buy” ratings from analysts.
What are the top picks among stocks under $10?
In the under-$10 range, Crescent Point Energy Corp. (CPG) emerges as a noteworthy consideration. Currently trading at $7.06, it boasts a one-year price target of $11.96 and enjoys a consensus “strong buy” rating from analysts.